 Juan Lessing
Concepts (112)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Teaching Rounds | 2 | 2021 | 64 | 1.340 |
Why?
| | Education, Medical | 2 | 2020 | 222 | 1.120 |
Why?
| | Education, Distance | 2 | 2020 | 38 | 0.860 |
Why?
| | Internship and Residency | 3 | 2021 | 944 | 0.840 |
Why?
| | Organizations | 1 | 2022 | 19 | 0.820 |
Why?
| | Hospital Medicine | 1 | 2023 | 82 | 0.790 |
Why?
| | Clinical Competence | 4 | 2022 | 901 | 0.730 |
Why?
| | Leadership | 1 | 2023 | 295 | 0.710 |
Why?
| | Remedial Teaching | 1 | 2019 | 4 | 0.690 |
Why?
| | Teaching | 1 | 2022 | 223 | 0.680 |
Why?
| | Education, Medical, Continuing | 1 | 2020 | 119 | 0.670 |
Why?
| | Anemia | 1 | 2021 | 144 | 0.670 |
Why?
| | Orbital Cellulitis | 1 | 2019 | 14 | 0.670 |
Why?
| | Education, Medical, Graduate | 2 | 2021 | 374 | 0.660 |
Why?
| | Comprehension | 1 | 2021 | 154 | 0.660 |
Why?
| | Congresses as Topic | 1 | 2020 | 198 | 0.650 |
Why?
| | Keratoconjunctivitis | 1 | 2019 | 3 | 0.650 |
Why?
| | Medical Staff, Hospital | 1 | 2019 | 75 | 0.650 |
Why?
| | Thrombocytopenia | 1 | 2021 | 177 | 0.650 |
Why?
| | Accidental Falls | 1 | 2021 | 150 | 0.640 |
Why?
| | Neisseria gonorrhoeae | 1 | 2019 | 20 | 0.640 |
Why?
| | Gonorrhea | 1 | 2019 | 54 | 0.600 |
Why?
| | Patient Safety | 1 | 2021 | 278 | 0.600 |
Why?
| | Decision Making | 1 | 2023 | 781 | 0.560 |
Why?
| | Cellulitis | 1 | 2016 | 45 | 0.550 |
Why?
| | Synovial Fluid | 1 | 2016 | 57 | 0.520 |
Why?
| | Purpura | 1 | 2015 | 13 | 0.520 |
Why?
| | Hair Diseases | 1 | 2015 | 6 | 0.520 |
Why?
| | Gout | 1 | 2016 | 37 | 0.510 |
Why?
| | Scurvy | 1 | 2015 | 12 | 0.510 |
Why?
| | Hair Follicle | 1 | 2015 | 44 | 0.510 |
Why?
| | Arthritis, Infectious | 1 | 2016 | 49 | 0.500 |
Why?
| | Communication | 1 | 2021 | 749 | 0.500 |
Why?
| | Uric Acid | 1 | 2016 | 148 | 0.480 |
Why?
| | Anti-Bacterial Agents | 2 | 2019 | 1477 | 0.380 |
Why?
| | Physicians | 1 | 2019 | 772 | 0.370 |
Why?
| | Humans | 25 | 2023 | 114935 | 0.360 |
Why?
| | Diet | 1 | 2015 | 1077 | 0.310 |
Why?
| | Internal Medicine | 2 | 2021 | 211 | 0.310 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 3 | 2013 | 50 | 0.290 |
Why?
| | Terminology as Topic | 2 | 2019 | 187 | 0.270 |
Why?
| | Diagnostic Errors | 2 | 2023 | 151 | 0.240 |
Why?
| | Diagnosis, Differential | 3 | 2019 | 1355 | 0.240 |
Why?
| | Professional Competence | 1 | 2023 | 84 | 0.210 |
Why?
| | Hip Injuries | 1 | 2021 | 16 | 0.190 |
Why?
| | Paracentesis | 1 | 2021 | 7 | 0.190 |
Why?
| | International Normalized Ratio | 1 | 2021 | 45 | 0.190 |
Why?
| | Ascites | 1 | 2021 | 33 | 0.180 |
Why?
| | Independent Living | 1 | 2021 | 84 | 0.180 |
Why?
| | Breast Neoplasms | 4 | 2013 | 1870 | 0.170 |
Why?
| | Clindamycin | 1 | 2019 | 12 | 0.170 |
Why?
| | Confidentiality | 1 | 2019 | 67 | 0.170 |
Why?
| | Patient Handoff | 1 | 2019 | 26 | 0.160 |
Why?
| | Liver Cirrhosis | 1 | 2021 | 228 | 0.160 |
Why?
| | Forecasting | 1 | 2020 | 333 | 0.160 |
Why?
| | Australia | 1 | 2019 | 207 | 0.160 |
Why?
| | Problem Solving | 1 | 2019 | 141 | 0.150 |
Why?
| | Receptors, Estrogen | 2 | 2011 | 372 | 0.150 |
Why?
| | Administration, Oral | 1 | 2019 | 731 | 0.140 |
Why?
| | Faculty, Medical | 1 | 2019 | 232 | 0.140 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 269 | 0.140 |
Why?
| | Electronic Health Records | 1 | 2023 | 802 | 0.140 |
Why?
| | Periodicals as Topic | 1 | 2019 | 181 | 0.140 |
Why?
| | Aged | 6 | 2021 | 19122 | 0.130 |
Why?
| | Crystallization | 1 | 2016 | 136 | 0.130 |
Why?
| | Directive Counseling | 1 | 2015 | 41 | 0.130 |
Why?
| | Health Behavior | 1 | 2021 | 704 | 0.130 |
Why?
| | Nutrition Assessment | 1 | 2015 | 75 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2021 | 834 | 0.120 |
Why?
| | United States | 2 | 2021 | 12211 | 0.120 |
Why?
| | Students | 1 | 2019 | 500 | 0.120 |
Why?
| | Physical Examination | 1 | 2015 | 220 | 0.110 |
Why?
| | Food | 1 | 2015 | 160 | 0.110 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 928 | 0.110 |
Why?
| | Livedo Reticularis | 1 | 2012 | 4 | 0.110 |
Why?
| | Adrenalectomy | 1 | 2012 | 60 | 0.110 |
Why?
| | Curriculum | 1 | 2019 | 845 | 0.100 |
Why?
| | Pheochromocytoma | 1 | 2012 | 54 | 0.100 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2012 | 81 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 2 | 2013 | 3053 | 0.090 |
Why?
| | Adult | 6 | 2019 | 30608 | 0.090 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 4635 | 0.090 |
Why?
| | Estrogen Antagonists | 1 | 2009 | 39 | 0.080 |
Why?
| | Hormone Replacement Therapy | 1 | 2009 | 77 | 0.080 |
Why?
| | Tamoxifen | 1 | 2009 | 192 | 0.080 |
Why?
| | Male | 4 | 2019 | 55663 | 0.080 |
Why?
| | Female | 6 | 2021 | 59580 | 0.070 |
Why?
| | Treatment Outcome | 3 | 2015 | 9105 | 0.070 |
Why?
| | Middle Aged | 5 | 2016 | 26806 | 0.060 |
Why?
| | Neoplasm Invasiveness | 2 | 2013 | 445 | 0.050 |
Why?
| | Feedback | 1 | 2019 | 145 | 0.040 |
Why?
| | Self Efficacy | 1 | 2019 | 355 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2019 | 978 | 0.030 |
Why?
| | Cohort Studies | 2 | 2011 | 4903 | 0.020 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2011 | 100 | 0.020 |
Why?
| | Mammography | 1 | 2011 | 106 | 0.020 |
Why?
| | Biopsy | 1 | 2013 | 1045 | 0.020 |
Why?
| | Carcinoma, Ductal | 1 | 2009 | 11 | 0.020 |
Why?
| | Neoadjuvant Therapy | 1 | 2011 | 305 | 0.020 |
Why?
| | Nitriles | 1 | 2009 | 151 | 0.020 |
Why?
| | Preoperative Care | 1 | 2011 | 317 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1126 | 0.020 |
Why?
| | Triazoles | 1 | 2009 | 130 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 6218 | 0.020 |
Why?
| | Survival Rate | 1 | 2011 | 1644 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2013 | 12544 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2011 | 863 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2009 | 1148 | 0.010 |
Why?
| | Prognosis | 1 | 2011 | 3344 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2011 | 4427 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2011 | 6364 | 0.010 |
Why?
| | Young Adult | 1 | 2012 | 10478 | 0.010 |
Why?
|
|
Lessing's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|